D. E. Shaw & Co. Inc. reduced its holdings in shares of Catalent Inc (NYSE:CTLT) by 34.7% during the 2nd quarter, Holdings Channel.com reports. The fund owned 667,307 shares of the company’s stock after selling 354,566 shares during the period. D. E. Shaw & Co. Inc.’s holdings in Catalent were worth $36,174,000 at the end of the most recent reporting period.
Several other institutional investors have also modified their holdings of the company. BlackRock Inc. boosted its position in shares of Catalent by 2.8% during the 2nd quarter. BlackRock Inc. now owns 14,307,589 shares of the company’s stock valued at $775,615,000 after acquiring an additional 388,615 shares in the last quarter. Champlain Investment Partners LLC boosted its position in Catalent by 1.9% in the first quarter. Champlain Investment Partners LLC now owns 3,913,500 shares of the company’s stock valued at $158,849,000 after buying an additional 74,670 shares in the last quarter. Highline Capital Management L.P. acquired a new position in Catalent in the second quarter valued at about $111,494,000. Invesco Ltd. boosted its position in Catalent by 11.9% in the second quarter. Invesco Ltd. now owns 1,774,766 shares of the company’s stock valued at $96,210,000 after buying an additional 188,998 shares in the last quarter. Finally, Viking Global Investors LP boosted its position in Catalent by 50.5% in the second quarter. Viking Global Investors LP now owns 1,595,579 shares of the company’s stock valued at $86,496,000 after buying an additional 535,066 shares in the last quarter.
In other news, SVP Steven L. Fasman sold 4,053 shares of the company’s stock in a transaction that occurred on Thursday, July 11th. The shares were sold at an average price of $54.04, for a total transaction of $219,024.12. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Gregory T. Lucier bought 2,000 shares of Catalent stock in a transaction dated Monday, September 9th. The shares were bought at an average price of $51.64 per share, for a total transaction of $103,280.00. The disclosure for this purchase can be found here. 1.40% of the stock is currently owned by corporate insiders.
A number of research firms have commented on CTLT. Morgan Stanley boosted their price target on shares of Catalent from $50.00 to $61.00 and gave the company an “overweight” rating in a research report on Wednesday, August 28th. Zacks Investment Research lowered shares of Catalent from a “buy” rating to a “hold” rating in a research report on Monday, September 16th. Robert W. Baird boosted their price target on shares of Catalent from $50.00 to $60.00 and gave the company an “outperform” rating in a research report on Wednesday, August 28th. Jefferies Financial Group upgraded shares of Catalent from a “hold” rating to a “buy” rating and boosted their price target for the company from $50.00 to $62.00 in a research report on Friday, June 21st. Finally, UBS Group boosted their price target on shares of Catalent to $64.00 and gave the company a “buy” rating in a research report on Tuesday, July 23rd. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Catalent currently has a consensus rating of “Buy” and an average price target of $57.00.
Shares of CTLT stock traded up $0.96 during trading hours on Friday, reaching $51.60. 893,662 shares of the company were exchanged, compared to its average volume of 824,434. Catalent Inc has a fifty-two week low of $29.23 and a fifty-two week high of $58.38. The stock’s fifty day moving average is $53.77 and its two-hundred day moving average is $48.72. The company has a market cap of $7.39 billion, a price-to-earnings ratio of 31.85, a P/E/G ratio of 2.50 and a beta of 1.65. The company has a debt-to-equity ratio of 1.71, a current ratio of 2.08 and a quick ratio of 1.70.
Catalent (NYSE:CTLT) last announced its earnings results on Tuesday, August 27th. The company reported $0.65 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.62 by $0.03. Catalent had a net margin of 5.46% and a return on equity of 15.89%. The company had revenue of $725.70 million for the quarter, compared to analyst estimates of $719.20 million. During the same period in the prior year, the business earned $0.67 earnings per share. Catalent’s quarterly revenue was up 5.9% on a year-over-year basis. On average, research analysts anticipate that Catalent Inc will post 1.8 earnings per share for the current year.
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel Technologies, Biologics and Specialty Drug Delivery, Oral Drug Delivery, and Clinical Supply Services. The Softgel Technologies segment formulates, develops, and manufactures prescription and consumer soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations.
Further Reading: Outstanding Shares, Buying and Selling Stocks
Want to see what other hedge funds are holding CTLT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Catalent Inc (NYSE:CTLT).
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.